Home > Rheumatology > EULAR 2019 > Rheumatoid Arthritis > Tapering of Prednisone in RA Patients Who Achieved Low Disease Activity or Remission with Tocilizumab

Tapering of Prednisone in RA Patients Who Achieved Low Disease Activity or Remission with Tocilizumab

Presented By
Prof. Gerd Burmester, Free University and Humboldt University of Berlin, Germany
Conference
EULAR 2019

Tapering prednisone, while remaining in at least low disease activity, may be an option for nearly two-thirds of rheumatoid arthritis (RA) patients who achieved remission or low disease activity on tocilizumab and low-dose prednisone.

According to current guidelines, patients with RA should typically receive the lowest necessary dose of glucocorticoid treatment, while avoiding doses ≥5 mg/day for longer than 3 to 6 months. However, many early or established RA patients receive ≥5 mg/day or higher doses varying between 3 up to 24 months. In addition, Prof. Gerd Burmester (Free University and Humboldt University of Berlin, Germany) noted in an interview that “physicians largely rely on personal experience when tapering glucocorticoids.” There is a lack of methodologically, appropriate clinical trials and guidelines for when and how to taper glucocorticoids, including prednisone.

Prof. Burmester compared glucocorticoid tapering versus continuation to m...



please login to read the entire article:


You need to register to read the entire article, please do so now.





Posted on